These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6415310)

  • 1. [Current clinical status of new anticancer drugs].
    Ogawa M
    Gan No Rinsho; 1983 Aug; 29(10):1049-52. PubMed ID: 6415310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status of clinical results of new antitumor drugs].
    Ogawa M
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro.
    Drewinko B; Yang LY; Barlogie B; Trujillo JM
    Cancer Res; 1983 Jun; 43(6):2648-53. PubMed ID: 6850582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
    Tolcher AW
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
    Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
    J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug interactions with anticancer agents].
    Furue H
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2231-6. PubMed ID: 3907502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation.
    Kharasch ED; Novak RF
    J Pharmacol Exp Ther; 1983 Aug; 226(2):500-6. PubMed ID: 6875860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
    Thomadaki H; Scorilas A
    Biol Chem; 2008 Nov; 389(11):1427-34. PubMed ID: 18783338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.
    Kluza J; Marchetti P; Gallego MA; Lancel S; Fournier C; Loyens A; Beauvillain JC; Bailly C
    Oncogene; 2004 Sep; 23(42):7018-30. PubMed ID: 15273722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide.
    Yokomizo A; Ono M; Nanri H; Makino Y; Ohga T; Wada M; Okamoto T; Yodoi J; Kuwano M; Kohno K
    Cancer Res; 1995 Oct; 55(19):4293-6. PubMed ID: 7671238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic aspects of lung cancer chemotherapy.
    Beard DB; Haskell CM
    Clin Chest Med; 1986 Sep; 7(3):505-13. PubMed ID: 3533403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracyclines in the treatment of gynecologic malignancies.
    Maluf FC; Spriggs D
    Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.